Holen Sie sich die Stockscreener-App
6.775
0.95%
-0.065
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting - The Manila Times
BioCryst Pharmaceuticals to Present Nine Abstracts on Hereditary Angioedema at 2026 AAAAI Annual Meeting - Quiver Quantitative
Shots every 3–6 months suppress HAE attacks in BioCryst trial data - Stock Titan
BioCryst to Present New HAE Data from ORLADEYO® - GlobeNewswire
What catalysts could drive BioCryst Pharmaceuticals Inc. stock higherMarket Performance Summary & Low Risk Profit Maximizing Plans - mfd.ru
Why BioCryst Pharmaceuticals Inc. stock is a must watch in 2025Earnings Miss & Weekly High Potential Stock Alerts - mfd.ru
BioCryst Acquisition Of Astria Highlights Rare Disease Focus And Valuation Gap - Yahoo Finance
Jim Cramer on BioCryst Pharmaceuticals: "Just Stay Away From That" - Finviz
BioCryst Uses Equity Grants To Support Rare Disease Pipeline And Talent - Sahm
Jim Cramer on BioCryst Pharmaceuticals: “Just Stay Away From That” - Insider Monkey
(BCRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Jim Cramer Commented on These 14 Stocks - Insider Monkey
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 - The Globe and Mail
ADARx Pharmaceuticals Appoints Donald Fong as CMO - Contract Pharma
BioCryst (BCRX) Grants Stock Options and RSUs to New Employees - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 | Nation/World | bdtonline.com - Bluefield Daily Telegraph
Will BioCryst's ORLADEYO Hit The $1 Billion Sales Mark? - RTTNews
BioCryst Pharmaceuticals, Inc. (BCRX) Investor Outlook: Exploring a Potential 226.80% Upside - DirectorsTalk Interviews
Biocryst expands HAE treatment portfolio with Astria acquisition - Angioedema News
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Steris (STE), Arcellx Inc (ACLX) and BioCryst (BCRX) - The Globe and Mail
BioCryst Pharmaceuticals Is Quietly Exploding – Is BCRX the Next Sleeper Biotech Rocket or a Total - AD HOC NEWS
BCRX: Analyst Maintains Rating but Lowers Price Target to $13 | - GuruFocus
Royal Bank Of Canada Lowers BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00 - MarketBeat
RBC Cuts Price Target on BioCryst Pharmaceuticals to $13 From $14, Keeps Outperform Rating - marketscreener.com
Is BioCryst Pharmaceuticals Inc. backed by strong institutional buyingRate Hike & AI Powered Buy/Sell Recommendations - Mfd.ru
Does Blackstone’s US$400 Million Deal and Astria Hires Change The Bull Case For BioCryst (BCRX)? - Sahm
Is BioCryst Pharmaceuticals Inc.’s growth already priced inJuly 2025 Final Week & AI Optimized Trade Strategies - mfd.ru
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A 198% Potential Upside for Investors - DirectorsTalk Interviews
(BCRX) Risk Channels and Responsive Allocation - Stock Traders Daily
Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Pressure And Rare Disease Pipeline Focus - Yahoo Finance
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema - Sahm
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Mixed Recent Share Price Performance - Sahm
Astria Therapeutics Completes Merger and Goes Private - TipRanks
BioCryst Closes Blackstone Loan and Astria Acquisition - TipRanks
BioCryst Pharmaceuticals Signs Loan Agreement With Blackstone and Lenders - TradingView
Astria Therapeutics Signs Loan Agreement Joinder With BioCryst Pharmaceuticals - TradingView
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 5.3%Still a Buy? - MarketBeat
BioCryst Completes Acquisition of Astria Therapeutics (ATXS) - GuruFocus
BioCryst completes $700 million acquisition of Astria Therapeutics - Investing.com
BioCryst Pharmaceuticals Completes Acquisition of Astria Therapeutics to Enhance HAE Portfolio - Quiver Quantitative
Hereditary Angioedema Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
BioCryst Pharmaceuticals, Inc. announced that it expects to receive $400 million in funding - marketscreener.com
BioCryst: The $700 Million Pivot From Oral Convenience To Injectable - Seeking Alpha
Clearside Biomedical Shares Surge Amid Bankruptcy Proceedings - AD HOC NEWS
Astria stockholders approve acquisition by BioCryst - Investing.com Australia
Astria stockholders approve acquisition by BioCryst By Investing.com - Investing.com South Africa
Astria Stockholders Vote to Approve Acquisition by BioCryst - citybiz
Astria stockholders vote to approve acquisition by BioCryst - marketscreener.com
Astria Therapeutics (ATXS) Stockholders Approve BioCryst Merger - GuruFocus
Astria Therapeutics Shareholders Greenlight Acquisition by BioCryst Pharmaceuticals - marketscreener.com
BioCryst: A Changed And Interesting Thesis For 2026 (NASDAQ:BCRX) - Seeking Alpha
Campbell & CO Investment Adviser LLC Decreases Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Is BioCryst Pharmaceuticals Inc. a defensive stockJuly 2025 Update & Consistent Profit Trade Alerts - bollywoodhelpline.com
Does BioCryst (BCRX) 2026 Revenue Guidance Reframe the ORLADEYO Growth Story for Investors? - simplywall.st
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Its New 2026 Revenue Guidance - Sahm
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.8%What's Next? - MarketBeat
0.63%
10.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):